Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4BDON)

• Drug Name: Methylprednisolone Drug Info
• Synonyms: Depo-medrol; M-predrol; Medrol; Medrol Acetate

Indication

Disease Entry	ICD 11	Status	REF
Acute adrenal insufficiency		Approved	[1]
Acute asthma	CA23	Approved	[1]
Addison disease	5A74.0	Approved	[1]
Allergic rhinitis	CA08.0	Approved	[1]
Angioedema	4A00.15	Approved	[1]
Aspiration pneumonitis		Approved	[1]
Autoimmune haemolytic anaemia	3A20	Approved	[1]
Bursitis		Approved	[1]
Cerebral edema	8D60.1	Approved	[1]
Chronic graft versus host disease		Approved	[1]
Congenital adrenal hyperplasia	5A71.01	Approved	[1]
Crohn disease	DD70	Approved	[1]
Dermatitis herpetiformis	EB44	Approved	[1]
Diamond-Blackfan anemia		Approved	[1]
Disorder of orbital region		Approved	[1]
Epicondylitis		Approved	[1]
Erythema multiforme		Approved	[1]
Exanthem		Approved	[1]
Fever	MG26	Approved	[1]
Granuloma annulare		Approved	[1]
Inflammatory bowel disease	DD72	Approved	[1]
Ischemia-reperfusion injury	DB98.B	Approved	[1]
Leukemia		Approved	[1]
Lupus nephritis	4A40.0Y	Approved	[1]
Microscopic polyangiitis		Approved	[1]
Miliary tuberculosis		Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Myeloproliferative neoplasm	2A20	Approved	[1]
Pneumocystis pneumonia	CA40.20	Approved	[1]
Primary cutaneous T-cell lymphoma		Approved	[1]
Psoriasis	EA90	Approved	[1]
Psoriatic arthritis	FA21	Approved	[1]
Rheumatic heart disease		Approved	[1]
Rheumatoid arthritis	FA20	Approved	[2]
Sarcoidosis	4B20.5	Approved	[1]
Seasonal allergic rhinitis	CA08.01	Approved	[1]
Serum sickness		Approved	[1]
Severe asthma	CA23	Approved	[1]
Skin disease	EA00-EM0Z	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Systemic lupus erythematosus	4A40.0	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
Acquired thrombocytopenia		Investigative	[1]
Asthma	CA23	Investigative	[1]
Beta-thalassemia major		Investigative	[1]
Classic Hodgkin lymphoma		Investigative	[1]
Follicular lymphoma	2A80	Investigative	[1]
Perennial allergic rhinitis	CA08.03	Investigative	[1]
Spinal cord injury	ND51.2	Investigative	[4]
Synovitis		Investigative	[1]
Trichinellosis		Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 6741
  ChEBI ID: CHEBI:6888
  CAS Number: CAS 83-43-2
  TTD Drug ID: DM4BDON
  VARIDT Drug ID: DR00128
  INTEDE Drug ID: DR1056
  ACDINA Drug ID: D00420

Molecule-Related Drug Atlas

Drug(s) Targeting Glucocorticoid receptor (NR3C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[10]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[5]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[11]
Fluticasone	DMGCSVF	Allergic rhinitis	CA08.0	Approved	[12]
Betamethasone Valerate	DMMIAXO	Dermatological disease	DA24.Y	Approved	[5]
Deflazacort	DMV0RNS	Duchenne dystrophy	8C70	Approved	[5]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[13]
Budesonide	DMJIBAW	Allergic rhinitis	CA08.0	Approved	[14]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[15]
Fluocinolone Acetonide	DMG2KI4	Choroiditis		Approved	[5]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[300]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[102]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[301]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[188]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[16]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[17]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[18]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[19]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[18]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[18]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[20]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[18]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[21]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[22]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[23]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[24]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[25]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[26]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[27]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[28]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[29]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[30]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[24]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[31]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[32]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[34]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[35]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[36]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[37]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[38]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[39]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[40]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[41]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[42]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[43]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[44]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[45]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[46]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[47]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[48]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[49]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[47]

Drug(s) Affected By Interleukin-6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[50]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[52]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[53]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[54]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[55]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[56]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[57]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Ceruletide	DM2WE5K	Caerulein stimulated gastric and pancreatic secretion	5A4Y	Approved	[58]

Drug(s) Affected By CCN family member 1 (CCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[64]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[65]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]

Drug(s) Affected By Phospholipid phosphatase 3 (PLPP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[70]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[75]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]

Drug(s) Affected By Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[77]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[79]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[81]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]

Drug(s) Affected By Calmegin (CLGN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[83]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[84]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[75]

Drug(s) Affected By D-3-phosphoglycerate dehydrogenase (PHGDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[71]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[87]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[87]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[87]

Drug(s) Affected By Receptor-interacting serine/threonine-protein kinase 2 (RIPK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[70]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[88]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[89]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[90]

Drug(s) Affected By Gasdermin-E (GSDME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[91]
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[95]

Drug(s) Affected By Toll-like receptor 2 (TLR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[97]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[98]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[99]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[96]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[101]

Drug(s) Affected By CCN family member 5 (CCN5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[102]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[8]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[103]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[104]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[105]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[106]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[107]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[108]

Drug(s) Affected By Antiviral innate immune response receptor RIG-I (RIGI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[110]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]

Drug(s) Affected By 2'-5'-oligoadenylate synthase 1 (OAS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[112]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[71]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[113]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[114]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[115]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[116]

Drug(s) Affected By Collagen alpha-1(I) chain (COL1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[117]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[118]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[119]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[121]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[122]
Ceruletide	DM2WE5K	Caerulein stimulated gastric and pancreatic secretion	5A4Y	Approved	[58]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[123]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[124]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[125]

Drug(s) Affected By Superoxide dismutase , mitochondrial (SOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[126]
Selenium	DM25CGV	N. A.	N. A.	Approved	[127]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[128]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[129]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[130]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[131]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[132]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[133]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]

Drug(s) Affected By Ubiquitin-like protein ISG15 (ISG15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[135]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[136]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[81]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]

Drug(s) Affected By Thrombospondin-1 (THBS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[102]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[142]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[143]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[79]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[144]

Drug(s) Affected By Asparagine synthetase (ASNS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[145]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[146]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[147]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[146]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[148]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[149]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[146]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[150]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[151]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[152]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[152]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[152]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[152]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[153]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[152]

Drug(s) Affected By Steryl-sulfatase (STS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Tazarotene	DM8SMD1	Acne vulgaris	ED80	Approved	[154]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Danazol	DML8KTN	Menorrhagia	GA20.50	Approved	[155]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[154]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[156]

Drug(s) Affected By Neuromedin-B (NMB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[157]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[79]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[158]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]

Drug(s) Affected By Stromelysin-2 (MMP10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[73]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[142]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[79]
Haloperidol	DM96SE0	Delirium		Approved	[159]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]

Drug(s) Affected By Growth-regulated alpha protein (CXCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Selenium	DM25CGV	N. A.	N. A.	Approved	[127]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[160]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[131]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[142]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[161]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[79]

Drug(s) Affected By Interferon alpha-inducible protein 6 (IFI6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[162]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[163]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[164]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[165]
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[166]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[167]

Drug(s) Affected By Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[168]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[169]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[170]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[171]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[172]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[173]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[174]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[52]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[175]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[54]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[152]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[176]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[177]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[152]

Drug(s) Affected By Interleukin-1 receptor antagonist protein (IL1RN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[131]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[157]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[178]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[179]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]

Drug(s) Affected By C-X-C motif chemokine 2 (CXCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Selenium	DM25CGV	N. A.	N. A.	Approved	[127]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[160]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[180]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[181]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]

Drug(s) Affected By C-X-C motif chemokine 3 (CXCL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[54]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[160]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[167]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[182]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[183]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Interferon-induced GTP-binding protein Mx1 (MX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[137]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[143]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[116]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[81]

Drug(s) Affected By Fibulin-1 (FBLN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[91]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[184]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[167]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[185]

Drug(s) Affected By Atypical chemokine receptor 3 (ACKR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[91]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[83]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[181]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[186]

Drug(s) Affected By 11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[187]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[188]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[142]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[189]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[190]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[191]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[187]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[189]

Drug(s) Affected By Adenosine receptor A2a (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[192]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[193]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[194]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[195]

Drug(s) Affected By CCN family member 2 (CCN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[102]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[187]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[157]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[196]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[145]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]

Drug(s) Affected By Myristoylated alanine-rich C-kinase substrate (MARCKS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[197]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[198]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]

Drug(s) Affected By Guanylate-binding protein 1 (GBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[120]
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[157]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[199]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]

Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[200]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[201]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[202]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[203]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[204]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[205]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[206]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[102]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[152]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[207]

Drug(s) Affected By Macrophage metalloelastase (MMP12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]

Drug(s) Affected By Interferon alpha-inducible protein 27, mitochondrial (IFI27)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[114]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[167]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[81]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[90]

Drug(s) Affected By Signal transducer and activator of transcription 1-alpha/beta (STAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[147]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[208]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[209]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[210]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[211]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[109]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[110]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]

Drug(s) Affected By Regulator of G-protein signaling 4 (RGS4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[212]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]

Drug(s) Affected By Prolargin (PRELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[64]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[167]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[213]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[214]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[69]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[215]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[216]

Drug(s) Affected By Spermine synthase (SMS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[217]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[83]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[218]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[8]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[219]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[220]

Drug(s) Affected By C-X-C chemokine receptor type 4 (CXCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[221]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[222]
Carfilzomib	DM48K0X	Multiple myeloma	2A83	Approved	[223]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[70]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[224]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[225]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[226]

Drug(s) Affected By C-C motif chemokine 20 (CCL20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[54]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[227]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]

Drug(s) Affected By Interferon-induced 35 kDa protein (IFI35)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[228]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[71]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[81]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]

Drug(s) Affected By DNA-binding protein inhibitor ID-3 (ID3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[52]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[229]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[168]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[230]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[231]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[229]

Drug(s) Affected By Tumor necrosis factor alpha-induced protein 2 (TNFAIP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[228]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[232]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[88]

Drug(s) Affected By Aldehyde oxidase (AOX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[160]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[131]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[233]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[212]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[183]

Drug(s) Affected By Bone marrow stromal antigen 2 (BST2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[81]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[234]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[157]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[212]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[183]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[235]

Drug(s) Affected By Neuronal membrane glycoprotein M6-b (GPM6B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[236]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[237]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]

Drug(s) Affected By Laminin subunit beta-3 (LAMB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[238]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[181]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[239]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[90]

Drug(s) Affected By Nidogen-2 (NID2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[91]
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[240]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[90]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]

Drug(s) Affected By Signal transducer and activator of transcription 4 (STAT4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[79]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[181]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[83]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[241]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[195]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[8]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[242]

Drug(s) Affected By 2'-5'-oligoadenylate synthase-like protein (OASL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[187]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[243]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[170]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[110]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[187]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[183]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]

Drug(s) Affected By Bcl-2-related protein A1 (BCL2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[244]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[245]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[246]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[247]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[248]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]

Drug(s) Affected By Lymphocyte antigen 6E (LY6E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[228]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[8]

Drug(s) Affected By Interferon-induced protein 44-like (IFI44L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[110]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[83]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]

Drug(s) Affected By E3 ubiquitin-protein ligase RNF19B (RNF19B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[230]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[249]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Amphoterin-induced protein 2 (AMIGO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[83]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[212]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[250]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]

Drug(s) Affected By Probable E3 ubiquitin-protein ligase HERC6 (HERC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[157]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[251]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[252]

Drug(s) Affected By Equilibrative nucleobase transporter 1 (SLC43A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[181]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Bortezomib	DMNO38U	Leukemia		Approved	[253]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[254]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[255]

Drug(s) Affected By Interferon-induced protein 44 (IFI44)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[116]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[81]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Bortezomib	DMNO38U	Leukemia		Approved	[253]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]

Drug(s) Affected By S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (RSAD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[141]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[181]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[74]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[81]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]

Drug(s) Affected By Nuclear receptor subfamily 4 group A member 3 (NR4A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[117]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[70]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[143]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[191]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[183]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[248]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Type II iodothyronine deiodinase (DIO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[256]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[257]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[258]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[185]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[259]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[90]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[257]

Drug(s) Affected By Interferon regulatory factor 7 (IRF7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[187]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[166]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[260]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[115]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[171]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[187]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]

Drug(s) Affected By Interferon-stimulated gene 20 kDa protein (ISG20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[261]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[187]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Interferon-induced helicase C domain-containing protein 1 (IFIH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[262]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[263]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]

Drug(s) Affected By Anthrax toxin receptor 1 (ANTXR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[217]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[79]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[75]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[212]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[183]

Drug(s) Affected By Interleukin-23 subunit alpha (IL23A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[264]
Misoprostol	DMHVJFK	Medical abortion	JA00.1Z	Approved	[265]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[253]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Bortezomib	DMNO38U	Leukemia		Approved	[266]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[267]

Drug(s) Affected By NADH dehydrogenase 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[268]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[183]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[195]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[8]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[242]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[269]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[270]

Drug(s) Affected By E3 ISG15--protein ligase HERC5 (HERC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[83]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[8]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[271]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[267]

Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[272]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[152]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[273]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[152]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[152]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[274]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[275]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[152]

Drug(s) Affected By Hypoxia-inducible lipid droplet-associated protein (HILPDA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[8]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[71]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[276]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[277]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[276]

Drug(s) Affected By 2'-5'-oligoadenylate synthase 3 (OAS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[94]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[8]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Coagulation factor VIII (F8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[278]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Betaine	DMGRZW2	Cystitis	GC00	Approved	[279]
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[280]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[251]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[195]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[213]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[281]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[76]

Drug(s) Affected By Myelin basic protein (MBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[114]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[75]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[282]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[283]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[183]
Bortezomib	DMNO38U	Leukemia		Approved	[253]

Drug(s) Affected By Glial fibrillary acidic protein (GFAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penicillin V	DMKVOYF	Acute otitis media	AB00	Approved	[117]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[117]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[284]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[285]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[114]
Haloperidol	DM96SE0	Delirium		Approved	[159]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[93]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[286]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[287]

Drug(s) Affected By 5-hydroxytryptamine receptor 3A (HTR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[117]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[271]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[288]
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[289]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[290]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[291]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[187]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[9]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[271]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[292]

Drug(s) Affected By Tyrosine aminotransferase (TAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[293]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[64]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[73]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[294]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[295]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[296]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[297]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[298]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[299]

Drug(s) Affected By Thrombopoietin (THPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[302]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Methamphetamine	DMPM4SK	Anxiety		Approved	[303]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[304]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[103]
Testosterone undecanoate	DMZO10Y	Hypogonadism	5A61.0	Approved	[305]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[306]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[307]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[214]

Drug(s) Affected By P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[308]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[309]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[310]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[311]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[82]
Asasantin	DMCZIHT	Cerebrovascular ischaemia	8B1Z	Approved	[312]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[313]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[314]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[315]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Modulator	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Gene/Protein Processing	[8]
2'-5'-oligoadenylate synthase 1 (OAS1)	OT8ZLOCY	OAS1_HUMAN	Gene/Protein Processing	[8]
2'-5'-oligoadenylate synthase 3 (OAS3)	OT6E5FYS	OAS3_HUMAN	Gene/Protein Processing	[8]
2'-5'-oligoadenylate synthase-like protein (OASL)	OTZ05YRP	OASL_HUMAN	Gene/Protein Processing	[8]
5-hydroxytryptamine receptor 3A (HTR3A)	OTAIV1AK	5HT3A_HUMAN	Gene/Protein Processing	[9]
Adenosine receptor A2a (ADORA2A)	OTVRBZ0I	AA2AR_HUMAN	Gene/Protein Processing	[8]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Gene/Protein Processing	[8]
Amphoterin-induced protein 2 (AMIGO2)	OTPAIT1O	AMGO2_HUMAN	Gene/Protein Processing	[8]
Anthrax toxin receptor 1 (ANTXR1)	OT5W1GPC	ANTR1_HUMAN	Gene/Protein Processing	[8]
Antiviral innate immune response receptor RIG-I (RIGI)	OTFIIC43	RIGI_HUMAN	Gene/Protein Processing	[8]

References

• [1] Methylprednisolone FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] ClinicalTrials.gov (NCT04341038) Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7088).
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.
• [7] Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
• [8] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [9] Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in xenopus oocytes. Anesthesiology. 2004 Sep;101(3):660-5. doi: 10.1097/00000542-200409000-00014.
• [10] Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
• [11] Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
• [12] Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
• [13] Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
• [14] PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
• [15] The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
• [16] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [17] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [18] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [19] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [20] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [21] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [22] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [23] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [24] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [25] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [26] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [27] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [28] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [29] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [30] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [31] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [32] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [33] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [34] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [35] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [36] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [37] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [38] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [39] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [40] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [41] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [42] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [43] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [44] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [45] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [46] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [47] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [48] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [49] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [50] Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.
• [51] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [52] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [53] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [54] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [55] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [56] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [57] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [58] Acinar cell-specific knockout of the PTHrP gene decreases the proinflammatory and profibrotic responses in pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G533-49. doi: 10.1152/ajpgi.00428.2013. Epub 2014 Jul 17.
• [59] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [60] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [61] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [62] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [63] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [64] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [65] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [66] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [67] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [68] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [69] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [70] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [71] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [72] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [73] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [74] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [75] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [76] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [77] Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood. 2002 Aug 1;100(3):1008-13. doi: 10.1182/blood.v100.3.1008.
• [78] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [79] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [80] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [81] White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. 2015 Jan;17(1):57-67. doi: 10.1038/ncb3075. Epub 2014 Dec 8.
• [82] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [83] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [84] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [85] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [86] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [87] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [88] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [89] Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 2009 Aug;30(8):1320-9. doi: 10.1093/carcin/bgp138. Epub 2009 Jun 5.
• [90] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [91] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [92] Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma. Chem Biol Interact. 2021 Dec 1;350:109704. doi: 10.1016/j.cbi.2021.109704. Epub 2021 Oct 13.
• [93] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [94] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [95] Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
• [96] Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
• [97] Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF-B signaling pathway. Immunobiology. 2011 Mar;216(3):367-73. doi: 10.1016/j.imbio.2010.07.011. Epub 2010 Aug 19.
• [98] Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 2010 Jun;199(2):110-20. doi: 10.1016/j.cancergencyto.2010.02.010.
• [99] A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. Thromb Res. 2012 Jul;130(1):45-51. doi: 10.1016/j.thromres.2011.12.009. Epub 2012 Jan 2.
• [100] Mechanical stress-activated immune response genes via Sirtuin 1 expression in human periodontal ligament cells. Clin Exp Immunol. 2012 Apr;168(1):113-24. doi: 10.1111/j.1365-2249.2011.04549.x.
• [101] Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1907-1911. doi: 10.1111/jdv.14437. Epub 2017 Aug 29.
• [102] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [103] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [104] WISP-2 as a novel estrogen-responsive gene in human breast cancer cells. Biochem Biophys Res Commun. 2000 Aug 18;275(1):108-14. doi: 10.1006/bbrc.2000.3276.
• [105] Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
• [106] Characterizing the genetic basis for nicotine induced cancer development: a transcriptome sequencing study. PLoS One. 2013 Jun 18;8(6):e67252.
• [107] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [108] The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics. 2010 Aug 13;3:37. doi: 10.1186/1755-8794-3-37.
• [109] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [110] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [111] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [112] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [113] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [114] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [115] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [116] Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
• [117] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [118] Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
• [119] Patterns of some extracellular matrix gene expression are similar in cells from cleft lip-palate patients and in human palatal fibroblasts exposed to diazepam in culture. Toxicology. 2009 Mar 4;257(1-2):10-6. doi: 10.1016/j.tox.2008.12.002. Epub 2008 Dec 9.
• [120] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [121] Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
• [122] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [123] The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am. 2001 Feb;83(2):201-11. doi: 10.2106/00004623-200102000-00007.
• [124] Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006 Apr;54(4):1298-308. doi: 10.1002/art.21723.
• [125] Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy. Invest Ophthalmol Vis Sci. 2012 Aug 31;53(9):5921-9. doi: 10.1167/iovs.12-9646.
• [126] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [127] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [128] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [129] Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radic Biol Med. 2001 Jan 15;30(2):148-53.
• [130] Cissus quadrangularis ethanol extract upregulates superoxide dismutase, glutathione peroxidase and endothelial nitric oxide synthase expression in hydrogen peroxide-injured human ECV304 cells. J Ethnopharmacol. 2012 Sep 28;143(2):664-72.
• [131] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [132] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [133] Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
• [134] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [135] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [136] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [137] Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009 Jun;8(6):3006-19.
• [138] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [139] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [140] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [141] Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
• [142] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [143] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [144] Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways. Life Sci. 2008 Mar 12;82(11-12):591-9. doi: 10.1016/j.lfs.2007.11.030. Epub 2007 Dec 23.
• [145] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [146] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [147] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [148] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [149] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [150] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [151] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [152] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [153] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [154] Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways. J Cell Biochem. 2006 Feb 1;97(2):327-50. doi: 10.1002/jcb.20579.
• [155] Synthesis and steroid sulphatase inhibitory activity of C19- and C21-steroidal derivatives bearing a benzyl-inhibiting group. Eur J Med Chem. 2001 Jul-Aug;36(7-8):659-71. doi: 10.1016/s0223-5234(01)01262-4.
• [156] Stilbene-based inhibitors of estrone sulfatase with a dual mode of action in human breast cancer cells. Arch Pharm (Weinheim). 2004 Dec;337(12):634-44. doi: 10.1002/ardp.200400904.
• [157] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [158] Folic acid induces cell type-specific changes in the transcriptome of breast cancer cell lines: a proof-of-concept study. J Nutr Sci. 2016 Apr 26;5:e17. doi: 10.1017/jns.2016.8. eCollection 2016.
• [159] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [160] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [161] Zinc induces chemokine and inflammatory cytokine release from human promonocytes. J Hazard Mater. 2011 Nov 30;196:335-41. doi: 10.1016/j.jhazmat.2011.09.035. Epub 2011 Sep 19.
• [162] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [163] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [164] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [165] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [166] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [167] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [168] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [169] Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):45-56. doi: 10.1007/s13539-011-0021-y. Epub 2011 Feb 26.
• [170] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [171] Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012 Dec;64(12):3856-66. doi: 10.1002/art.37691.
• [172] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [173] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [174] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [175] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [176] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [177] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [178] Altered cytokine profiles of human retinal pigment epithelium: oxidant injury and replicative senescence. Mol Vis. 2013;19:718-28. Epub 2013 Mar 21.
• [179] Indomethacin and ibuprofen effect on IL-1ra production by mononuclear cells of preterm newborns and adults. Biol Neonate. 2002 Aug;82(2):73-7. doi: 10.1159/000063090.
• [180] Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells. J Cell Biochem. 2012 Oct;113(10):3143-52. doi: 10.1002/jcb.24191.
• [181] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [182] Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer. 2011 May 1;117(9):2004-16. doi: 10.1002/cncr.25687. Epub 2010 Nov 8.
• [183] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [184] Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis. Eur Rev Med Pharmacol Sci. 2014;18(24):3877-88.
• [185] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [186] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [187] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [188] Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
• [189] Testosterone stimulates adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in a depot-specific manner in children. J Clin Endocrinol Metab. 2010 Jul;95(7):3300-8.
• [190] Role of calcitriol and cortisol on human adipocyte proliferation and oxidative and inflammatory stress: a microarray study. J Nutrigenet Nutrigenomics. 2008;1(1-2):30-48. doi: 10.1159/000109873. Epub 2007 Oct 16.
• [191] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [192] Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther. 2012 Jun 8;14(3):R138. doi: 10.1186/ar3871.
• [193] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [194] New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signal. 2007 Sep;3(4):339-46. doi: 10.1007/s11302-007-9068-9. Epub 2007 Sep 19.
• [195] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [196] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [197] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [198] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [199] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [200] Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
• [201] Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
• [202] Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
• [203] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [204] Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
• [205] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [206] Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
• [207] A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
• [208] Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes. J Biol Chem. 1999 Jun 18;274(25):17580-6. doi: 10.1074/jbc.274.25.17580.
• [209] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [210] Molecular mechanisms underlying the inhibition of IFN--induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem. 2011 Feb;112(2):675-83. doi: 10.1002/jcb.22976.
• [211] Quercetin and Its Fermented Extract as a Potential Inhibitor of Bisphenol A-Exposed HT-29 Colon Cancer Cells' Viability. Int J Mol Sci. 2023 Mar 15;24(6):5604. doi: 10.3390/ijms24065604.
• [212] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [213] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [214] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [215] High-throughput data integration of RNA-miRNA-circRNA reveals novel insights into mechanisms of benzo[a]pyrene-induced carcinogenicity. Nucleic Acids Res. 2015 Mar 11;43(5):2525-34. doi: 10.1093/nar/gkv115. Epub 2015 Feb 17.
• [216] Linking site-specific loss of histone acetylation to repression of gene expression by the mycotoxin ochratoxin A. Arch Toxicol. 2018 Feb;92(2):995-1014.
• [217] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [218] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [219] 5-Fluorouracil: identification of novel downstream mediators of tumour response. Anticancer Res. 2004 Mar-Apr;24(2A):417-23.
• [220] Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect. 2007 Nov;115(11):1646-53. doi: 10.1289/ehp.10283.
• [221] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [222] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [223] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [224] Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-B signaling in cervical cancer. Ann Surg Oncol. 2014 Dec;21 Suppl 4:S687-95. doi: 10.1245/s10434-014-3812-5. Epub 2014 Jul 22.
• [225] Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Leuk Res. 2006 Feb;30(2):123-35. doi: 10.1016/j.leukres.2005.06.009. Epub 2005 Jul 25.
• [226] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [227] Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009 Dec 24;114(27):5512-21. doi: 10.1182/blood-2009-02-204834. Epub 2009 Oct 14.
• [228] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [229] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [230] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [231] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [232] Immediate up-regulation of the calcium-binding protein S100P and its involvement in the cytokinin-induced differentiation of human myeloid leukemia cells. Biochim Biophys Acta. 2005 Sep 10;1745(2):156-65.
• [233] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [234] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [235] Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4336-44. doi: 10.1158/1078-0432.CCR-07-0015.
• [236] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [237] Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15;66(24):12009-18.
• [238] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [239] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [240] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [241] Role of phenytoin in wound healing: microarray analysis of early transcriptional responses in human dermal fibroblasts. Biochem Biophys Res Commun. 2004 Feb 13;314(3):661-6. doi: 10.1016/j.bbrc.2003.12.146.
• [242] Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 Feb 18;24(2):165-7. doi: 10.1021/tx1004419. Epub 2011 Feb 4.
• [243] Differently expressed long noncoding RNAs and mRNAs in TK6 cells exposed to low dose hydroquinone. Oncotarget. 2017 Oct 4;8(56):95554-95567. doi: 10.18632/oncotarget.21481. eCollection 2017 Nov 10.
• [244] Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000 Feb;14(2):262-70. doi: 10.1038/sj.leu.2401650.
• [245] 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct. 2005;30(1):1-6. doi: 10.1247/csf.30.1.
• [246] Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis. Leukemia. 2010 Aug;24(8):1476-86. doi: 10.1038/leu.2010.117. Epub 2010 Jun 3.
• [247] Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
• [248] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [249] Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res. 2005 May 1;65(9):3837-45.
• [250] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [251] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [252] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [253] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [254] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [255] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [256] The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes. 2007 Mar;56(3):767-76. doi: 10.2337/db06-1488.
• [257] Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. Endocrinology. 2009 Apr;150(4):1976-83. doi: 10.1210/en.2008-0938. Epub 2008 Nov 26.
• [258] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [259] Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases. Toxicol Sci. 2019 Apr 1;168(2):430-442. doi: 10.1093/toxsci/kfy302.
• [260] Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon- inhibition. Acta Pharm Sin B. 2020 Jun;10(6):1061-1072. doi: 10.1016/j.apsb.2020.01.016. Epub 2020 Jan 31.
• [261] Small Molecule Antipsychotic Aripiprazole Potentiates Ozone-Induced Inflammation in Airway Epithelium. Chem Res Toxicol. 2019 Oct 21;32(10):1997-2005. doi: 10.1021/acs.chemrestox.9b00149. Epub 2019 Sep 11.
• [262] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [263] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [264] Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
• [265] Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009 Mar 16;206(3):535-48. doi: 10.1084/jem.20082293. Epub 2009 Mar 9.
• [266] Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer. 2007 Oct 22;97(8):1099-105. doi: 10.1038/sj.bjc.6604003. Epub 2007 Sep 25.
• [267] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [268] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [269] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [270] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [271] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [272] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [273] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [274] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [275] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [276] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [277] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [278] Effect of metal cations on the conformation and inactivation of recombinant human factor VIII. J Pharm Sci. 2004 Oct;93(10):2549-57. doi: 10.1002/jps.20167.
• [279] Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A. PLoS One. 2012;7(9):e44505. doi: 10.1371/journal.pone.0044505. Epub 2012 Sep 4.
• [280] Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood. 2005 Nov 1;106(9):3043-8. doi: 10.1182/blood-2005-03-1307. Epub 2005 Jul 28.
• [281] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [282] Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Liver Int. 2008 Aug;28(7):997-1010. doi: 10.1111/j.1478-3231.2008.01744.x. Epub 2008 Apr 15.
• [283] Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. doi: 10.1111/j.1365-2567.2007.02574.x. Epub 2007 Mar 7.
• [284] miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol. 2013 Aug;29(4):239-57. doi: 10.1007/s10565-013-9250-5. Epub 2013 Aug 1.
• [285] Aspirin-induced blockade of NF-kappaB activity restrains up-regulation of glial fibrillary acidic protein in human astroglial cells. Biochim Biophys Acta. 2006 Mar;1763(3):282-9. doi: 10.1016/j.bbamcr.2006.01.005. Epub 2006 Feb 21.
• [286] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [287] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [288] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [289] Interactions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriers. Br J Pharmacol. 2005 Oct;146(4):543-52. doi: 10.1038/sj.bjp.0706351.
• [290] Activation and modulation of recombinantly expressed serotonin receptor type 3A by terpenes and pungent substances. Biochem Biophys Res Commun. 2015 Nov 27;467(4):1090-6. doi: 10.1016/j.bbrc.2015.09.074. Epub 2015 Oct 9.
• [291] The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptors. Anesth Analg. 2008 Jul;107(1):107-12. doi: 10.1213/ane.0b013e31817342c2.
• [292] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [293] Microtubule disarray in primary cultures of human hepatocytes inhibits transcriptional activity of the glucocorticoid receptor via activation of c-jun N-terminal kinase. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Dec;148(2):135-9.
• [294] Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. PLoS One. 2014 Aug 1;9(8):e104010.
• [295] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [296] Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chem Biol Interact. 2009 May 15;179(2-3):288-96.
• [297] Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol. 2006 Jul;70(1):329-39.
• [298] Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2017 Apr;91(4):1815-1832.
• [299] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [300] Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
• [301] Comparative effects of microtubules disruption on glucocorticoid receptor functions in proliferating and quiescent cells. Int J Toxicol. 2010 May-Jun;29(3):326-35. doi: 10.1177/1091581810366486.
• [302] 1,25(OH)2-vitamin D3 inhibits proliferation and decreases production of monocyte chemoattractant protein-1, thrombopoietin, VEGF, and angiogenin by human annulus cells in vitro. Spine (Phila Pa 1976). 2008 Apr 1;33(7):755-65. doi: 10.1097/BRS.0b013e3181695d59.
• [303] Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
• [304] Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun 29;103(1):52-60.
• [305] Levonorgestrel enhances spermatogenesis suppression by testosterone with greater alteration in testicular gene expression in men. Biol Reprod. 2009 Mar;80(3):484-92.
• [306] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [307] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [308] Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 Aug 26;108(8):939-44. doi: 10.1161/01.CIR.0000085163.21752.0A. Epub 2003 Aug 11.
• [309] Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J (Engl). 2000 Mar;113(3):236-40.
• [310] Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res. 2004;113(3-4):197-204. doi: 10.1016/j.thromres.2004.03.002.
• [311] Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med. 2004;36(7):552-7. doi: 10.1080/07853890410017386.
• [312] Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol. 2004 Sep 24;499(3):315-24. doi: 10.1016/j.ejphar.2004.07.114.
• [313] Effects of histamine 2 receptor antagonists on endothelial-neutrophil adhesion and surface expression of endothelial adhesion molecules induced by high glucose levels. J Diabetes Complications. 2007 Jan-Feb;21(1):50-5. doi: 10.1016/j.jdiacomp.2006.02.002.
• [314] Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis. 2008 Jul;199(1):55-64. doi: 10.1016/j.atherosclerosis.2007.10.038. Epub 2008 Feb 21.
• [315] Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000 Jun;83(6):688-95. doi: 10.1136/heart.83.6.688.